Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Unaudited Condensed Interim Consolidated Statements of Cash Flows

v3.20.2
Unaudited Condensed Interim Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating activities:        
Net and comprehensive loss for the period $ (1,640,633) $ (14,472,866) $ (3,551,875) $ (42,755,746)
Items not involving cash:        
Amortization 39,383 7,291 88,953 13,466
Stock based compensation 286,111 740,051 720,774 991,408
Warrant liability-fair value adjustment (2,872,069) (6,609,952) 4,793,375 3,866,673
Warrant liability-foreign exchange adjustment 48,065 142,682 9,972 36,625
Non-cash issue costs 764,132
Non-cash settlement included in payables 2,090,200
Non-cash note payable expenses and accrued interest 32,908 186,730
Changes in non-cash working capital items:        
Amounts receivable, prepaid expenses and deposits 264,468 1,294,599 (328,951) (283,330)
Accounts payable and accrued liabilities (737,993) 5,736,133 (5,613,707) 5,783,889
Cash used in operating activities (4,579,760) (13,162,062) (840,397) (32,347,015)
Financing activities:        
Net proceeds from issuance of common shares and warrants [1] 741,225 (2,997) 23,490,929 31,374,911
Proceeds from note payable 1,500,000
Repayment of lease liabilities (23,518) (33,761)
Cash provided by financing activities 717,707 (2,997) 24,957,168 31,374,911
Investing Activities:        
Purchase of property, plant and equipment (79,498) (79,498)
Additions to patents (72,292) (125,198) (175,852) (178,956)
Cash used in investing activities (151,790) (125,198) (255,350) (178,956)
Increase (Decrease) in cash and cash equivalents (4,013,843) (13,290,257) 23,861,421 (1,151,060)
Cash and cash equivalents, beginning of the period 28,689,756 23,610,440 814,492 11,471,243
Cash and cash equivalents, end of the period 24,675,913 10,320,183 24,675,913 10,320,183
Cash and cash equivalents comprise:        
Cash 20,483 1,392,741 20,483 1,392,741
Cash Equivalents 24,655,430 8,927,442 24,655,430 8,927,442
Cash and cash equivalents, end of the period $ 24,675,913 $ 10,320,183 $ 24,675,913 $ 10,320,183
[1] Includes net proceeds from the issuance of common share equivalents (see note 9a).